About CB Therapeutics
CB Therapeutics is a Healthcare company based in San Diego (United States) founded in 2015 by Sher Ali Butt and Jacob Vogan. Biosynthetic cannabinoids are produced from sugar using engineered microbes. It operates on a Technology-Driven Models and Product & Retail Models model. CB Therapeutics has raised $150 thousand across 3 funding rounds from investors including Y Combinator and EvoNexus. The company has 15 employees. Its chief executive, as recorded, is Sher Ali Butt. CB Therapeutics offers products and services including Precision Fermentation Platform, Psychedelic Therapeutics, Cannabinoids, and Animal-Free Food Ingredients. Its focus areas include Biotechnology, Synthetic Biology, Food & Beverage and Food Technology. Its legal entity is CB Therapeutics Inc. Its competitors include MindMed, Delix Therapeutics and Mindstate; 2 of its 3 listed competitors have raised funding.
Company details
CB Therapeutics is engaged in the design, development, and manufacture of compounds using precision fermentation and synthetic biology. Solutions are developed to address challenges in mental health, physical wellness, food scarcity, and nutrition. The company is involved in producing psychedelic therapeutics, cannabinoids, and animal-free food ingredients. Operations span across neuroscience, clinical research, nutraceuticals, cannabis, cosmetics, and food and beverage sectors. A proprietary yeast platform is utilized to enhance natural metabolic processes for sustainable production.
- Headquarters San Diego, United States
- Employees 15
- Founders Sher Ali Butt, Jacob Vogan
- SectorsHealthcare
- Phone•••• ••••
- Website cbthera.com
- Social LinkedIn X Facebook Instagram
- Legal Name Cb Therapeutics Inc.
- Total Equity Funding$150K (USD)
in 3 rounds
- InvestorsY Combinator
& 1 more
- Employee Count15
Products & Services of CB Therapeutics
CB Therapeutics offers a comprehensive portfolio of products and services, including Precision Fermentation Platform, Psychedelic Therapeutics, Cannabinoids, and Animal-Free Food Ingredients.
Platform used for sustainable compound production via fermentation.
Therapeutics developed for mental health treatment solutions.
Cannabinoids produced for clinical and research applications.
Ingredients created for sustainable food production systems.
Funding Insights of CB Therapeutics
CB Therapeutics has successfully raised a total of $150K across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150,000
- Total Rounds 3
- Investors Count 2
All 3 funding rounds of CB Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | Series A | – | – | – | |
| Jun 2018 | $150,000 | Seed | – | – | |
| Jul 2017 | Seed | – | EvoNexus | – |
2 investors in total: 2 institutional.
Investors in CB Therapeutics
CB Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Y Combinator and EvoNexus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
12-18 month incubation programs are provided for startups in California. | evonexus.org | San Diego, United States |
Investor details for CB Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CB Therapeutics
6 people are tracked at CB Therapeutics (3 in leadership, 3 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Sher Ali Butt | Co-Founder & CEO | Leadership |
Jacob Vogan | Co-Founder & CSO | Leadership |
Erin Scott | Director, Microbiology | Leadership |
Diana Castillo | Lab Manager | Team |
Adam Mintz | Business Development | Team |
Thanos Karavokiris, MIBA | Operations & Finance Executive | Team |
Complete people profiles for CB Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CB Therapeutics
3 dated milestones of CB Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded CB Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A,.
Competitors of CB Therapeutics
CB Therapeutics has 3 listed competitors in our database, 2 of them funded. They include MindMed, Delix Therapeutics and Mindstate.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mindmed.co | 2019 | New York, United States | 74 | Psychedelic-based therapies for brain health disorders are developed. | ||
| delixtherapeutics.com | 2019 | Menlo Park, United States | $70M | 7 | Non-hallucinogenic therapeutics for neurological disorders are developed. | |
| mindstate.design | 2021 | Pittsburgh, United States | $24.32M | Psychedelic-based therapeutics for mental health conditions are developed. |
Detailed competitors of CB Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as CB Therapeutics (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cb Therapeutics
Complete news archive for CB Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CB Therapeutics
CB Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
CB Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sher Ali Butt is the CEO of CB Therapeutics, as recorded in our data. They have also founded this company.
CB Therapeutics is a funded company, having raised a total of $150K across 3 funding rounds to date.
CB Therapeutics has 15 employees.
CB Therapeutics is engaged in the design, development, and manufacture of compounds using precision fermentation and synthetic biology. Solutions are developed to address challenges in mental health, physical wellness, food scarcity, and nutrition. The company is involved in producing psychedelic therapeutics, cannabinoids, and animal-free food ingredients. Operations span across neuroscience, clinical research, nutraceuticals, cannabis, cosmetics, and food and beverage sectors. A proprietary yeast platform is utilized to enhance natural metabolic processes for sustainable production.
CB Therapeutics's top competitors include MindMed, Delix Therapeutics and Mindstate.
CB Therapeutics offers Precision Fermentation Platform, Psychedelic Therapeutics, Cannabinoids, and Animal-Free Food Ingredients.
CB Therapeutics has 2 investors. Key investors include Y Combinator, and EvoNexus.
CB Therapeutics operates through Cb Therapeutics Inc..